Module 2: Immunotoxicity Studies: Why, When, and How to Conduct?

Recorded On: 03/27/2025

image
image


With the surge of immunotherapies and gene/cell therapies in the past two decades, the need to conduct immunotoxicity studies has increased dramatically. The studies needed for such programs are often case-by-case, and there is little harmonization between organizations. This module focuses on the considerations, principles, and applicable regulatory guidances to design and conduct an immunotoxicity program for major drug modalities.

This eLearning module covers several key areas related to immunotoxicity studies. The module will begin with a review of immunotoxicity testing, highlighting the surge in immunotherapies, gene/cell therapies, and the resulting growing need for immunotoxicity studies. The module will discuss the immunotoxicity assays required to support these programs and how the design differs from traditional immunotoxicity testing. Additionally, the module will provide a brief overview of differences in immune responses between nonclinical species and humans. It will also explore the considerations and applicable regulatory guidances for designing immunotoxicity studies for major drug modalities highlighting the case-by-case nature of these studies and the current lack of harmonization between organizations.

Florence G. Burleson, PhD

Florence G. Burleson, PhD

Consultant

Burleson Research Technologies, Inc.

Dr. Burleson received her PhD from the Department of Microbiology at the University of Notre Dame and a Master of Science in Financial Management and Technology Commercialization from North Carolina State University (NCSU). She has more than 30 years of professional experience in government, pharmaceutical, and contract research. She is the co-founder of Burleson Research Technologies, Inc. (BRT), a CRO specializing in immunotoxicology. Dr. Burleson has served as a Study Director conducting GLP-compliant studies for immunological, functional, and host resistance immunotoxicity assessments. As Executive VP and Senior Director of Nonclinical Studies, she provides oversight and direction for nonclinical studies programs and is responsible for budgets and financial management at BRT.

Dr. Burleson is a member of the American College of Toxicology (ACT) and Society of Toxicology (SOT), and a Fellow of the Academy of Toxicological Sciences (ATS). She was elected to the ACT Outreach Committee in 2013 and the ACT Council in 2016. She was Vice-President, President-Elect, and President (2022-2023) of ACT. She has also served on the SOT Finance Committee and is a past President of the SOT Immunotoxicology Specialty Section. Dr. Burleson was Chair of the Scientific Liaison Coalition (SLC), a coalition of societies to increase the impact of the science of toxicology to improve public health. She currently serves on the Editorial Board of the International Journal of Toxicology and on the Editorial Board of Toxicology Research Application.

Marie-Soleil Piche, PhD

Marie-Soleil Piche, PhD

Scientific Director of the Immunology Group

Charles River Laboratories

Dr. Marie-Soleil Piche is the Scientific Director of the Immunology group at Charles River Laboratories and specializes in nonclinical and clinical immune safety assessment of biotherapeutic drugs. She obtained her Bachelor’s degree in Immunology at McGill University and her Master of Science in Immunotoxicology at the Armand Frappier Institute. She completed a PhD in the field of autoimmune disease, studying the role of autoantibodies in the pathogenesis of lupus. Prior to joining Charles River, Dr. Piche worked at a small biotech company where she was responsible for developing cell-based assays to study the pharmacodynamics of various biotherapeutic drugs. She is an active member of the HELSI/ITC working group, where she co-leads the Education and Outreach group, and of the APPS, where she participates in the Immunogenicity and qPCR working groups. She is also the past president of the ITSS SOT. Dr. Piche is a co-author on several methods, best practices, and validation white papers.

Key:

Complete
Failed
Available
Locked
Module 2: Immunotoxicity Studies: Why, When, and How to Conduct?
Module 2: Immunotoxicity Studies: Why, When, and How to Conduct?, Florence Burleson, PhD, and Marie-Soleil Piche, PhD
Recorded 03/27/2025  |  90 minutes
Recorded 03/27/2025  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.